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Abstract
Background: PALB2 protein was recently identified as a partner of BRCA1 and BRCA2 which determines their
proper function in DNA repair.
Methods: Initially, the entire coding sequence of the PALB2 gene with exon/intron boundaries was evaluated by
the PCR-SSCP and direct sequencing methods on 70 ovarian carcinomas. Sequence variants of interest were further
studied on enlarged groups of ovarian carcinomas (total 339 non-consecutive ovarian carcinomas), blood samples
from 334 consecutive sporadic and 648 consecutive familial breast cancer patients, and 1310 healthy controls from
central Poland.
Results: Ten types of sequence variants were detected, and among them four novel polymorphisms: c.2996
+58T>C in intron 9; c.505C>A (p.L169I), c.618T>G (p.L206L), both in exon 4; and c.2135C>T (A712V) in exon 5 of
the PALB2 gene. Another two polymorphisms, c.212-58A>C and c.2014G>C (E672Q) were always detected together,
both in cancer (7.5% of patients) and control samples (4.9% of controls, p = 0.2). A novel germline truncating
mutation, c.509_510delGA (p.R170fs) was found in exon 4: in 2 of 339 (0.6%) unrelated ovarian cancer patients, in 4
of 648 (0.6%) unrelated familial breast cancer patients, and in 1 of 1310 controls (0.08%, p = 0.1, p = 0.044,
respectively). One ovarian cancer patient with the PALB2 mutation had also a germline nonsense mutation of the
BRCA2 gene.
Conclusions: The c.509_510delGA is a novel PALB2 mutation that increases the risk of familial breast cancer.
Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a
recurrent mutation for Polish population.
Background
PALB2 protein [OMIM #610355, a partner and localizer
of BRCA2] was recently identified in a complex with
BRCA2 (Breast Cancer 2) protein [1]. PALB2 supports
BRCA2 stability and determines its localization in the
nucleus after DNA damage [1]. Relocation of PALB2
and BRCA2 to damaged chromatin is regulated by
BRCA1 (Breast Cancer 1) protein [2]. These three pro-
teins form a complex in which PALB2 acts as a bridge
between BRCA1 and BRCA2 [2]. In cells depleted of
PALB2, DNA repair pathway dependent on the BRCA1/
2 is disrupted [1,2]. This suggests that inactivation of
the PALB2 gene may cause similar biological and
phenotypic changes as inactivation of the BRCA1 or
BRCA2 genes; the latter is responsible for a fraction of
breast and ovarian cancers, and a dysfunction of BRCA2
alone - for the Fanconi anemia (FA) syndrome.
FA syndrome is a genetic disorder caused by germline
biallelic mutations in one of 13 genes (including
FANCD1/BRCA2 and FANCN/PALB2) of the so-called
FA/BRCA pathway; this pathway controls the repair of
double strand-breaks and the response to DNA cross-
linking agents [3,4]. Studies on FA patients provide evi-
dence that biallelic mutations of the PALB2 gene are
responsible for one of the syndrome’s subtypes, which is
very similar to the one caused by inactivation of the
BRCA2 gene [5,6].
Mutations of the BRCA1 and BRCA2 genes are the
best known alterations of the FA/BRCA pathway. Het-
erozygous germline mutations of these genes predispose
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ovarian cancer to age 70 years for women with a
BRCA1 or BRCA2 mutation is estimated at about 40%
and 10%, respectively [7]. The cooperation between
BRCA2 and PALB2 during the DNA repair process and
similarity in clinical features of the FA syndrome caused
by biallelic mutations of BRCA2 and PALB2 genes sug-
gest the role of PALB2 alterations in carcinogenesis. To
date, PALB2 alterations have been associated with famil-
ial breast [8-13] and pancreatic [14,15] cancers. To our
knowledge, PALB2 gene has not been extensively stu-
died in ovarian cancer patients.
We demonstrate a novel inherited monoallelic dele-
tion of the PALB2 gene in ovarian and breast cancer
patients which seems to be a recurrent mutation for the
population of central Poland.
Methods
Subjects
The study was performed on a series of 339 non-conse-
cutive patients with ovarian cancer and 982 patients
with breast cancer; all patients were Caucasian women
from central Poland.
Ovarian cancer patients
The analysis was performed on tumor fragments (n =
339); patients’ blood samples were used to confirm
germline origin of the detected variants only. The sam-
ples were collected in two Warsaw hospitals (Institute of
Oncology and Brodnowski Hospital) between the years
1995 and 2007. These hospitals treat cancer patients
from central Poland. Mean age of patients was 56 years
(range 17-88). Distribution of cases in appropriate age
intervals in the group studied was comparable to that in
the whole population of ovarian cancer patients in
Poland [16]. Tumors were classified histologically
according to the criteria of the World Health Organisa-
tion [17]. There were 231 (68%) serous carcinomas, 33
(10%) endometrioid, 15 (4%) mucinous, 26 (8%) clear
cell, 17 (5%) undifferentiated and 17 (5%) other type
carcinomas. BRCA1 mutational status (exons 2, 5, 11
and 20) had been previously determined in the majority
of ovarian carcinomas (n = 243), and 39 (16%) were
positive [18]. A few carcinomas were also studied for
BRCA2 mutations in exons 2, 3, 11 (c.3035-6629) and
25 (Moes et al., data not published).
Breast cancer patients
DNA from the peripheral blood leukocytes was analyzed
in 334 sporadic and 648 familial breast cancer cases, the
latter with at least one first-, second- or third-degree
relative affected by breast and/or ovarian cancer. In 40
families with third-degree relative affected, additional
criteria were employed: carcinomas developing in a
proband and/or a relative before the age of 50, meta-
chronous or synchronous cancers diagnosed in a pro-
band or a relative, or non-breast and non-ovarian
cancers diagnosed in first- or second-degree relatives.
T h ep r o b a n d sw e r ep a t i e n t so ft h ef o l l o w i n gd e p a r t -
ments of the Institute of Oncology: Breast Tumors and
Reconstructive Surgery, and Genetic Counselling.
BRCA1 mutations (exons 2, 5, 11 and 20) had been pre-
viously detected for the purpose of counselling in 75 of
982 breast cancer patients (8.3%). The mean age of
patients was 50 (range 21-81) and 48 years (range 24-
85) for the sporadic and familial breast cancers,
respectively.
Controls
As a control, we used 1310 blood samples from unre-
lated Caucasian women from central Poland. These
samples were anonymously collected in Warsaw blood
donation centers between November 2005 and February
2009 (n = 1142). A part of control blood samples (n =
168) were collected among employees and cancer-free
patients from Brodnowski Hospital in Warsaw. Mean
age of females from the control group was 32 years
(range 18 to 75).
Patients gave their written informed consent to be
included in the study. Anonymous blood donors gave
informed consent. The study was approved by the
bioethics committee of the Institute of Oncology (ref.
no. 39/2007).
Molecular genetic methods
All 13 PALB2 exons with intron/exon boundaries were
initially screened for variants in 70 non-consecutive
ovarian carcinomas by the PCR-SSCP and sequencing
methods. Sequence variants of interest were further
studied in larger groups of ovarian carcinomas and in
control blood samples (see: Results). The germline ori-
gin of changes detected in ovarian carcinomas was
confirmed in blood samples from those patients. The
analyses were performed in the Department of Molecu-
lar Pathology. Blood from breast cancer patients was
screened only for the c.509_510delGA PALB2 deletion
in the Department of Endocrinology, with the use of
the dHPLC method.
DNA extraction
Fresh ovarian cancer specimens were snap-frozen and
stored at -68°C. Cryostat sections were cut and evalu-
ated by a pathologist (JK) as to the sufficient content of
tumor tissue. Blood samples were collected in vials
which contained EDTA, frozen and stored at -68°C.
DNA from both ovarian carcinomas and blood samples
was extracted with the use of proteinase K and the
QIAamp Mini kit (Qiagen), and stored in the AE buffer
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patients was isolated with the Genomic Midi AX kit
(A & A Biotechnology, Gdansk, Poland).
PCR - Polymerase Chain Reaction
DNA fragments were amplified by the PCR method. Pri-
mers (presented in Table 1) were designed using the
free Primer3 software [19] and the PALB2 genomic
sequence, obtained from the NCBI genome browser
[GenBank: NG_007406.1].
PCR mixture was prepared according to a standard
method (Applied Biosystems PCR kit). PCR reaction was
carried out for 36 cycles in a programmable thermal
cycler (Biometra) with denaturation at 94°C, annealing
at 56-58°C (depending on the exon) and extension at
72°C, for 30 sec each.
Single strand conformational polymorphism analysis
(SSCP)
All thirteen coding exons of the PALB2 gene were
screened by the SSCP method. In our experience, this
method detects 90% of all alterations, and 100% of dele-
tions and insertions [20]. PCR products were denatured
with 0.1 M NaOH containing 2 mM EDTA, at 55°C for
15 min. Immediately after 95% formamide, 0.05% xylene
cyanol and 0.05% bromphenol blue were added, the
samples were loaded to polyacrylamide gels (1:39 N, N’-
methylenebisacrylamide to acrylamide in 0.5 × TBE with
10% glycerol). Electrophoresis was performed at 100 V,
for 16-24 hours at room temperature. DNA bands were
visualised by the silver-staining method compilated from
several procedures.
Denaturing High-Performance Liquid Chromatography
DNA from breast cancer patients was screened for
PALB2 c.509_510delGA only (with Ex 4b-F and Ex 4b-R
primers), using the dHPLC method carried out on auto-
mated dHPLC instrumentation (Transgenomic Inc).
Crude PCR products were eluted with linear acetonitryle
gradient. The gradient and the temperature required for
successful resolution of heteroduplex molecules was
determined with the use of the dHPLC melting algo-
rithm (Transgenomic Inc). Mutation positive and nega-
tive controls for the screened mutation were always run
with each set of samples. The heterozygous profiles
were identified by visual inspection of the chromato-
grams, on the basis of appearance of additional, earlier
eluting peaks.
Sequencing
We sequenced all variants detected by the SSCP and
dHPLC. PCR products were purified by exonuclease I
and alkaline phosphatase treatment, and then sequenced
with the use of fluorescent automated method (BigDye
Terminator Cycle Sequencing Kit v3.1, Applied Biosys-
tems) with ABI PRISM 377 DNA sequencer.
PALB2 Haplotyping
DNA extracted from blood samples of PALB2 mutation
carriers was genotyped with the use of three markers
Table 1 PALB2 gene primers sequences
Exon Forward primer Reverse primer
1 GATTTAATTGGCCGGAGTTT GGGTGGTCAGATGATACTGC
2 - 3 CTTGCCCAGTATTGTTTGGTG GCAGGCATAAGTGAATGGTC
4a TCATCTGCCTGAATGAAATG TGAGTGAATCAGTGCCAAAG
4b CAAGAACATTTTCCCCACAG GGAGGAATGTGTTCAAGGTG
4c AGGGCGACTACAGTTCCTTT TGCAGAAAGAGGAGAGGTTG
4d TTGATGGCAGGAATGAAAAT GCAACTGCCTTCCTAGACAA
4e ATGCACAGGACAACCAAGTT TTGGCCCTGTCACTTTTTAG
5a TGTCTGTTTTGTTGGGTTTTG TCCATGCGTTTAGGACTCAG
5b TGCTCAGAAAAACCAGTGGA AGCAAGTTCGTCCAGCAAC
5c CCCTCAAGGCTCCTATGAAA GGCATTTCATTCCTTCAGAGA
6 GTGGGTAATGCAGGCAGAC TGTTTTTCTGAATCTGTTTACCAA
7 TTTGCATAAAACAGCACTCG TTTGGTAAGCTGCCCATCTA
8 TGATAAATTTTGGAAAATCTGGA CTGCACTTAAAACCAGCTGAC
9 ACTCCTCACATCACCCCATT TATTACACCCCCAGCACAGA
10 CGGAGAAGGGCTACCTAGAG GCAACACAAAACCACAATCA
11 TTGTTTGTTGGAAGAATGTGA CGGGGAAGGTTTGTTCATTA
12 AGAGCCTATCGGTCATTGCT TTCAGAATGTCCCACCCATA
13 GGATTTTTGTTCCTGTTGCTG TCTCCTTTATATTTAAAACTCCAAAAA
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D16S403 [UniSTS:150021], and D16S417
[UniSTS:67206]. Primer sequences were obtained from
the NCBI [21] UniSTS database. Marker and PALB2
gene positions were reckoned from NCBI [21] Homo
sapiens chromosome 16 genomic contig (reference
sequence: NT_010393.16). The loci were amplified by
PCR (as described earlier, at the annealing temperature
of 58°C) with the use of fluorescently labelled (6-FAM
dye) forward primer. PCR products were diluted in ster-
ile water, in a volume depending on reaction efficiency.
The dilution at the volume of 0.8 μlw a sm i x e dw i t h8
μl of formamide (SIGMA) and 0.4 μlo ft h es t a n d a r d
(Gene Scan 500 ROX, Applied Biosystems). The mixture
was denaturated for 5 min at 95°C and then cooled on
ice. Electrophoresis was performed in the ABI PRISM
377 DNA sequencer. Data were analyzed using the Peak
Scanner Software v1.0 (Applied Biosystems).
Immunohistochemical stainings
Markers of basal/luminal types were evaluated immuno-
histochemically with the use of the following antibodies:
anti-CK5/6 (DAKO, clone D5/16B4), anti-CK14 (Novo-
castra, clone NCL-L-LL002), anti-CK17 (DAKO, clone
IR620), anti-EGFR (DAKO, clone K1994), anti-CD117
(DAKO, clone A4502). All immunostainings were per-
formed against negative controls. Non-neoplastic mam-
mary gland structures served as intrinsic positive
controls.
Statistical analysis
Differences between the compared groups were analyzed
by the two-sided Fisher’s exact test [22]. The level of
statistical significance was set at <0.05.
Results
The initial screening of 70 ovarian carcinomas revealed
nine substitutions and one deletion of the PALB2 gene.
These alterations, and the final number of the samples
studied, are shown in Table 2.
Substitutions (studied in ovarian cancer patients only)
Nine substitutions were detected, four of which are
novel (Table 2). Two sequence variants, i.e. c.212-
58A>C in intron 3 and c.2014G>C in exon 5 were
always detected together, both in cancer and control
samples (p = 0.2). The majority of carcinomas and con-
trols carrying these alterations were heterozygous for
exon 5 and intron 3. Only one tumor and one control
DNA were homozygous, and there were alleles C in
both polymorphic sites.
c.509_510delGA deletion
We discovered a novel 2 base-pair deletion
c.509_510delGA in exon 4 of the PALB2 gene (Figure 1,
Table 2). It resulted in p.R170fs and created a premature
stop codon at position 183.
Table 2 Sequence variants in the PALB2 gene (in brackets - groups on which they were studied)
Exon Nucleotide change Effect Frequency in cancers Frequency in healthy controls SNP Id# or references
4* c.509-510delGA p.R170fs ovarian cancer
0.6% (2/339)
familial breast cancer
0.6% (4/648)
sporadic breast cancer
0 (0/334)
0.08% (1/1310) novel
Analyzed in ovarian cancers only
4* c.505C>A p.L169I 0 0.08% (1/1310) novel
4* c.618T>G p.L206L 0 0.08% (1/1310) novel
4* c.656A>G p.D219G 0 0.08% (1/1310) rs45594034:A>G
5** c.2014G>C p.E672Q 7.5% (15/200) 4.9% (16/326) rs45532440:G>C
5 c.2135C>T p.A712V 0.5% (1/200) 0.3% (1/326) novel
12 c.3300T>G p.T1100T 4.3% (3/70) Not studied rs45516100:T>G
Intron
3** c.212-58A>C 7.5% (15/200) 4.9% (16/326)
6 c.2586+58C>T 5.7% (4/70) Not studied rs249954:C>T
9 c.2996+58T>C 1.4% (1/70) Not studied novel
(GenBank accession number: genomic DNA- NG_007406.1, mRNA and protein- NM_024675.3)
# NCBI’s [21] SNP database
* confirmed by the SSCP and sequencing in separate PCR reactions
** in our study these polymorphisms were always detected together
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The alteration c.509_510delGA was detected in 2 of 339
ovarian cancers (0.6%) and in 1 of 1310 controls (0.08%;
p = 0.1). The deletion was present in both tumor and
blood DNA of the two patients. The analysis of sequen-
cing diagrams (Figure 1) of tumor sample number 375
(about 30% of stromal cell contamination) and blood
DNA of the same patient suggests the loss of heterozyg-
osity at this locus. LOH was also observed at two of the
three studied microsatellite loci (D16S481 and D16S403,
data not shown).
One of the two patients with the deletion (tumor
number 293) was diagnosed with a poorly differentiated
endometrioid carcinoma at the age of 61 (The Federa-
tion Internationale de Gynecologie et d’Obstetrique sta-
ging system - FIGO IIIC, histological grade 3). She
reported a history of cancers in her father’s family. The
father had a stomach cancer diagnosed at the age of 67,
his sister had a lung cancer (age unknown), his brother
had an unknown cancer at an unknown age. This
patient also carried a nonsense germline mutation i.e. c.
C4513T (Q1429X) in the BRCA2 gene.
The other patient (tumor number 375) was diag-
nosed with a poorly differentiated serous carcinoma at
the age of 54 (FIGO IIIC, histological grade 3). She
reported a history of cancers in her mother and her
mother’s sisters (thyroid and pancreatic carcinomas
mentioned, age unknown). No mutations in exons 2, 3,
11 (c.3035-6629) and 25 of the BRCA2 gene were
found.
Both of these patients died and we did not have a
chance to confirm these data.
Breast cancer patients
Screening of 982 consecutive sporadic or familial breast
cancer patients for c.509_510delGA resulted in detection
of the additional four mutation carriers. The deletion
was found in 4/648 (0.6%) familial breast cancer patients
versus 1/1310 controls (p = 0.044).
Histopathological features of breast carcinomas from
four of the deletion carriers are presented in Table 3.
All but one had triple (ER, PR, HER2)-negative pheno-
type. To characterize breast carcinomas with the PALB2
mutation more specifically, we evaluated the expression
of CK5/6, CK14, CK17, EGFR and CD117 (Table 3).
Two carcinomas were of the basal type and two of the
luminal type.
Pedigree diagrams were available for three patients
(Figure 2). The pedigree was not available for the patient
number 893, but she stated a breast cancer in her
grandmother at the age of 87.
Haplotype analysis
Genotyping of the seven c.509_510delGA deletion car-
riers was performed with three microsatellite markers:
D16S417 which is distal to PALB2, and D16S481 and
Figure 1 The c.509_510delGA detected in the PALB2 gene in ovarian carcinomas. SSCP gel (in the middle) - shifted bands are indicated by
arrows; on sequencing diagrams the deletion site is indicated by arrows.
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Proband no. Age Type, grade ER, PR HER2 CK5/6, CK17, EGFR CK14 CD117
802 53 ductal, G2 -- ++ -
2076 62 ductal, G3 -- - + -
893 44 ductal, G3
bifocal
+- - - +
1540 47 medullary - - + + -
(focal +)
ER-estrogen receptor, PR- progesterone receptor, HER2-human epidermal growth factor receptor 2, CK- cytokeratin, EGFR- epidermal growth factor receptor,
CD117-C-kit receptor
B - 1540
C - 2076
A - 802
Br - 47y Br - 36y
20y 17y
Sto - 76y
Sto - 63y Liv - 65y
Lu - 72y
 Br - 40y
 Br - 53y 52y
19y 33y
 Br - 74y
 Br - 68y
Br - 62y
Pan - 60y
86y 84y
80y 71y 77y 83y
76y y 8 3 y 1 6
69y 42y
70y
70y
Figure 2 Pedigrees of breast cancer families with PALB2 mutations. Probands with confirmed mutation are indicated by an arrow. Br -breast
cancer, Sto -stomach cancer, Liv -liver cancer, Lu - lung cancer, Pan - pancreatic cancer.
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presented in Table 4. There was no common haplotype
for all PALB2 mutations carriers with regard to the
three markers analyzed.
Discussion
We discovered a novel PALB2 germline deletion,
c.509_510delGA, located in exon 4. It may be expected
that due to this deletion PALB2 protein is shortened to
169 amino acids from 1186 amino acids of the wild type
and it is devoid of C-terminal domain (with WD40
repeats). WD40 motifs are thought to be responsible for
protein-protein interactions and they seem to be neces-
sary for BRCA2/PALB2 complex formation [11]. It was
shown that PALB2 mutants (229delT, 2521delA and
c.1592delT) that lacked C-terminal domain had highly
reduced BRCA2 binding capacity and were defective in
the repair of double-strand breaks and mitomycin C-
induced damages [10,11]. To date, all PALB2 gene
alterations detected in families with breast cancer or FA
disease were frameshift or nonsense changes, leading to
the expression of a truncated protein. These data
strongly support the assumption that the deletion
detected in this study results in the production of an
inactive protein. Silent and missense sequence variants
of the PALB2 gene have been detected in previous stu-
dies in both cancer samples and in control tissues, but
none of those variants have been strongly associated
with cancer susceptibility [9,10,12].
Our study proves that PALB2 alterations contribute to
the familial but not to the sporadic breast cancer in
Poland. This is in agreement with previous reports, in
which alterations of the PALB2 gene were predomi-
nantly associated with familial breast cancer [9-13].
Some authors reported PALB2 mutations also in pan-
creatic cancer [14,15], male breast cancer [9] and in a
single prostate cancer family [10]. Pancreatic cancer was
mentioned at least twice in the family histories of our
PALB2 mutation carriers.
The low frequency of PALB2 mutations (0.6%)
observed in our study is similar to that noticed for
breast cancer by other authors [8,9,11-13]. Only Erkko
et al. [10] found a higher rate of mutations in the famil-
ial breast cancer: 2.7%. In their study, however, the rate
of the mutations in the control population was also rela-
tively high (0.2%). No other study except Erkko’se ta l .
[10] and our study found PALB2 truncating mutations
in control populations.
We are the first to present a PALB2 truncating muta-
tion in a patient with medullary breast carcinoma. To
date, such alterations have been detected predominantly
in ductal breast carcinomas. In agreement with data pre-
sented by Heikkinen et al. [23], our study suggests that
breast cancers with PALB2 mutations are predominantly
triple-negative ones; however, their phenotype does not
completely overlap with the basal type.
In our study, PALB2 alterations did not associate with
ovarian cancer risk. In addition, the PALB2 deletion was
accompanied by a germline BRCA2 nonsense mutation
in one ovarian cancer patient (Moes et al., unpublished
data). A similar observation was published by Heikkinen
et al. [23] who found two breast cancer patients with a
PALB2 deletion among 104 BRCA2 mutation carriers.
Interestingly, the presence of these two alterations in
carcinomas appears to be more frequent than just one
occurring by chance, considering the low frequency of
PALB2 and BRCA2 mutations in control populations.
To date, PALB2 gene alterations have not been exten-
sively studied in ovarian cancer patients. Erkko et al.
[24] found three (0.5%) ovarian cancer patients with
PALB2 gene mutations in 593 unselected ovarian cancer
cases screened for the PALB2 c.1592delT alteration,
identified earlier in breast cancers [10]. Another dys-
function of PALB2 detected in ovarian cancer was its
expression silencing by promoter hypermethylation (in 4
of 53 sporadic cases) [25]. These studies, together with
our data suggest that PALB2 protein may be defective
or insufficient in some rare ovarian carcinomas;
Table 4 Results of genotyping of PALB2 mutation carriers
Proband no. Marker
position bp
D16S403
22,977,651
D16S481
23,188,290
PALB2
23,554,483*
D16S417
23,717,034
293 Ov. Ca. 2, 3 1, 2 c.509-510delGA 2, 4
375 Ov. Ca. 2, 6 1, 2 c.509-510delGA 2, 4
ZB649 Control 4, 3 1, 2 c.509-510delGA 3, 4
802 Br. Ca. 1, 6 3, 2 c.509-510delGA 2, 4
2076 Br. Ca. 4, 5 1, 1 c.509-510delGA 2, 1
893 Br. Ca. 4, 3 1, 2 c.509-510delGA 3, 4
1540 Br. Ca. 4, 3 1, 1 c.509-510delGA 2, 4
Alleles for each microsatellite marker were numbered according to the size. Ov. Ca. - ovarian cancer patients; Control - a PALB2 mutation carrier from the control
group; Br. Ca. - breast cancer patients
* the position of PALB2 gene on chromosome 16 (NCBI reference sequence: NT_010393.16); the position of the deletion is 23,587,357 bp
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ovarian cancer development needs elucidation.
It is unclear how the PALB2 deficiency contributes to
cancer development. It has been suggested that PALB2
participates in breast carcinogenesis through haploinsuf-
ficiency and/or the dominant-negative effect. In the
majority of breast cancers with PALB2 gene mutations,
the loss of heterozygosity (LOH) was not observed
[10,11]. The only evidence of deletion of the wild-type
allele was presented by Garcia et al. [12]. In our study,
t h e r ew a sas u s p i c i o no fL O Ha tPALB2 locus in one
ovarian carcinoma with PALB2 deletion. The regular
allele of PALB2 gene may also be eliminated by promo-
ter hypermethylation (as above). Such dysfunction was
revealed not only in ovarian but also in sporadic breast
cancers [25]. Since wild-type PALB2 proteins oligomer-
ize at damaged DNA [26], truncated PALB2 mutants
may possibly complex with wild type protein, thus, dis-
turbing its proper function. In addition, other molecular
changes may cooperate with PALB2 deficiency in cancer
development.
Some of PALB2 gene alterations in breast cancer were
suggested to be founder mutations for other ethnic
groups [8,10]. The presence of the same deletion in
seven unrelated women in our study might suggest that
this was a founder mutation for the examined popula-
tion from central Poland. Although the genotype analy-
sis of the mutation carriers showed differences in the
haplotypes, one cannot exclude an ancient founder
mutation. More detailed analysis is necessary to deter-
mine the origin of this alteration.
Our study had some limitations. The entire coding
sequence of the PALB2 gene was screened in 70 non-
consecutive ovarian cancers only; the sensitivity of the
SSCP ranges from 70% to 95%, according to different
publications [27,28], and it is 90% in our laboratory [20].
Thus, some PALB2 alterations (particularly of the mis-
sense type) could have been missed. Nevertheless, a
practical value of this study is that the c.509_510delGA
should be searched for in Polish families with breast
cancer.
Conclusions
The c.509_510delGA is a novel PALB2 mutation that
increases the risk of familial breast cancer. Occurrence
of the same PALB2 alteration in seven unrelated women
suggests that c.509_510delGA (p.R170fs) is a recurrent
mutation for population from Poland. It may be useful
to include this PALB2 mutation to a list of alterations
that should be searched for in Polish families with
breast cancer.
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